Manulife MPF Healthcare Fund
Manulife Global Select (MPF) Scheme
Data as of 2026-06-30
Straight talk on this fund
- Risk class 5, near the top of the scale. Worst calendar year on record: 2016 (-3.2%). That kind of drawdown separates the patient from the panicked.
- Top 10 holdings (Merck & Co., Inc, Novartis AG ADRJohnson & Johnson, Eli Lilly and Co.…) are 52.5% of the fund — over half the fund in ten names. The manager is betting big on a few stocks rather than owning the whole market. The top three (Merck & Co., Inc, Novartis AG ADRJohnson & Johnson, Eli Lilly and Co.) alone are 21.7%: when those names move, the fund moves with them.
- The objective promises a diversified portfolio, but 52.5% sits in the top 10 — that's concentration, not diversification. The label and the portfolio are telling different stories.
- In its best calendar year (2019) it made 9.4%; in its worst (2016) it lost 3.2% — that range tells you what you're signing up for.
- For monthly contributors, volatility can be a friend (buy more when down). Near retirement, that ride needs a second thought. When markets are choppy, position size itself is a decision.
Manager's LensWhat the portfolio reveals about the manager's thinking
Top-10 holdings are 52.5% of the fund. Merck & ., at 7.3% is the largest single position. The top three together are 21.7%. This is a concentrated portfolio. High conviction — or high concentration risk, depending on your view. Within the top 10, by sector: healthcare 33.3%. Healthcare dominates the top 10 at 33.3% — this is a sector bet, not a diversified mix. Within the top 10, by geography: US 26.5%, Europe 6.9%. 10 of the top 10 holdings also sit in peers' top 10 — high overlap with the category consensus.
No single macro theme dominates. The portfolio is positioned to move with broad market direction rather than any specific cycle. In a choppy, liquidity-tightening environment that neutrality is defensive; in a trending market it means keeping pace, not leading. One caveat: concentration amplifies macro moves. When funding liquidity tightens, concentrated portfolios tend to chop harder than diversified ones.
At the stock level there are no outsized single-name risks. The portfolio's behaviour will be driven by sector and market moves, not individual company events.
Concentrated healthcare exposure at 33.3% of top-10; top-10 concentration 52.5%. Manager runs a disciplined, benchmark-aware portfolio (10/10 top holdings overlap peers). No strong cyclical tilt — stock selection, not macro rotation, will drive returns. Note: near-term liquidity tightening amplifies concentrated-portfolio volatility. High concentration means higher volatility; longer holding periods help smooth cycle swings — best as a satellite, not a single holding.
Investment Objective
To provide long term capital growth. Invests on a diversified basis mainly in shares of companies in health care and related industries, covering mainly in pharmaceutical, healthcare equipment & services, food & drug retails, managed care business and biotechnology sectors
Trailing Returns ⓘ
| 3 Months | 1 Year | 3 Years | 5 Years | 10 Years | Since Launch | YTD | |
|---|---|---|---|---|---|---|---|
| Cumulative | +6.77% | +22.65% | +24.73% | +29.80% | +86.88% | +251.00% | +3.38% |
| Annualised | — | — | +7.65% | +5.36% | +6.45% | +7.12% | — |
Calendar Year Returns ⓘ
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Return (%) | +18.28% | -1.55% | +3.95% | -6.06% | +18.86% |
Returns are net of fees. Past performance is not indicative of future returns.
Dollar Cost Averaging Return ⓘ
Cumulative Return
| 3 Months | YTD | 1 Year | 3 Years | 5 Years | 10 Years | Since Launch | |
|---|---|---|---|---|---|---|---|
| Return (%) | N/A | N/A | +10.19% | +15.21% | +20.07% | +43.31% | +114.58% |
Annualised Return
| 3 Years | 5 Years | 10 Years | Since Launch | |
|---|---|---|---|---|
| Return (% p.a.) | +9.41% | +7.24% | +6.99% | +7.78% |
Calendar Year Return
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Return (%) | +11.96% | +2.30% | +5.17% | -7.64% | +13.79% |
Fund Commentary
The world equity markets performed very well in the second quarter, albeit with elevated volatility caused by daily headlines from the Middle East. Investors gradually grew more confident that the war in Iran would wind down quickly and have only a limited impact on global growth, leading to a significant rebound in stocks off their March lows. The markets were further boosted by corporate earnings that came in well above expectations, particularly for US technology companies. Artificial intelligence (AI) continued to be an important theme in the markets, fueling outsized gains for semiconductor and memory stocks. South Korea and Taiwan were notable beneficiaries of this trend, helping the broad-based emerging market (EM) indexes deliver strong returns. The healthcare sector advanced during the period. The healthcare providers and services, life sciences tools and services, and pharmaceuticals sub-sectors advanced, while the healthcare equipment and supplies and biotechnology sub-sectors declined.
Portfolio Allocation
Top 10 Holdings
| # | Security name | Holdings Weight |
|---|---|---|
| 1 | Eli Lilly and Co. | 9.78% |
| 2 | Johnson & Johnson | 7.29% |
| 3 | AbbVie Inc. | 5.18% |
| 4 | AstraZeneca PLC | 5.08% |
| 5 | Amgen Inc. | 4.16% |
| 6 | UnitedHealth Group Inc. | 3.19% |
| 7 | Roche Holding Ltd | 3.17% |
| 8 | Vertex Pharmaceuticals Inc. | 2.85% |
| 9 | Medtronic Plc | 2.82% |
| 10 | Stryker Corp. | 2.73% |
| Total | 46.25% |
Fees & Charges
The fund expense ratio shows the total annual cost of running this fund as a percentage of its assets. It is already reflected in the fund price and returns. When comparing similar funds, fees are one of the few factors you can control.
FER is a backward-looking figure from the fund's financial year, taken from provider fact sheets and audited annual reports. It may not yet reflect announced fee cuts.
More funds in this scheme
Related news
- Nov 16, 2026 October Final: HK$8,671 Gone in a Month — 2026’s First Back-to-Back Falls Are Now Confirmed
- Nov 15, 2026 One Month, 17.36 Points Apart: October’s Best MPF Fund Gained 6.31%, the Year’s Leader Fell 11.05%
- May 9, 2013 Gold crashes and H7N9: how to position in turbulent markets?
- Nov 6, 2012 Switching MPF? Better Stubborn About Quality: Why Avoid Japan Equity Funds?
- Aug 10, 2012 MPF bond funds: the overlooked all-rounder for offence and defence